Literature DB >> 9509270

Clostridium difficile infection.

C P Kelly1, J T LaMont.   

Abstract

Clostridium difficile infection is associated with broad-spectrum antibiotic therapy and is the most common cause of infectious diarrhea in hospital patients. Pathogenic strains of C. difficile produce two protein exotoxins, toxin A and toxin B, which cause colonic mucosal injury and inflammation. Infection may be asymptomatic, cause mild diarrhea, or result in severe pseudomembranous colitis. Diagnosis depends on the demonstration of C. difficile toxins in the stool. The first step in management is to discontinue the antibiotic that caused diarrhea. If diarrhea and colitis are severe or persistent, oral metronidazole is the treatment of choice. Oral vancomycin is also effective, but it is more expensive than metronidazole and its widespread use may encourage the proliferation of vancomycin-resistant nosocomial bacteria. Diarrhea and colitis usually improve within three days after a patient starts taking metronidazole or vancomycin, but 20% suffer a relapse of diarrhea when these agents are discontinued.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9509270     DOI: 10.1146/annurev.med.49.1.375

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  126 in total

1.  p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis.

Authors:  M Warny; A C Keates; S Keates; I Castagliuolo; J K Zacks; S Aboudola; A Qamar; C Pothoulakis; J T LaMont; C P Kelly
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization.

Authors:  H Genth; J Selzer; C Busch; J Dumbach; F Hofmann; K Aktories; I Just
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  Bacterial Infections of the Colon.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-06

4.  Pseudomembranous Colitis Caused by C. difficile.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-06

5.  Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota.

Authors:  Vincent B Young; Thomas M Schmidt
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

6.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

7.  Integration of metabolism and virulence by Clostridium difficile CodY.

Authors:  Sean S Dineen; Shonna M McBride; Abraham L Sonenshein
Journal:  J Bacteriol       Date:  2010-08-13       Impact factor: 3.490

Review 8.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

Review 9.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.